V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
Research Institute of General Pathology and Pathophysiology, Moscow, Russia.
Bull Exp Biol Med. 2021 Jan;170(3):312-315. doi: 10.1007/s10517-021-05058-x. Epub 2021 Jan 16.
The mechanisms underlying cardioprotective activity of compound ALM-802 were studied in experiments on rats with chronic post-infarction heart failure. Real-time PCR showed that compound ALM-802 (daily intraperitoneal injections in a dose of 2 mg/kg for 28 days starting from day 91 after myocardial infarction modeling) restored the expression of genes encoding β1- (p=0.00001) and β2-adrenoreceptors (p=0.01) and type 2 ryanodine receptors (p=0.008) in the myocardium that was reduced in control animals. These effects can serve as the basis for the ability of the compound to reduce the intensity of remodeling and increase the inotropic function of the left heart ventricle shown earlier in this model.
研究了化合物 ALM-802 的心脏保护作用的机制，该化合物在患有慢性心肌梗死后心力衰竭的大鼠实验中进行了研究。实时 PCR 显示，化合物 ALM-802（从心肌梗死后模型建立后的第 91 天开始，每天腹腔注射 2 毫克/千克，共 28 天）恢复了编码β1-（p=0.00001）和β2-肾上腺素受体（p=0.01）以及 2 型兰尼碱受体（p=0.008）的基因在心肌中的表达，而在对照组动物中，这些基因的表达减少。这些作用可以作为该化合物降低该模型中先前显示的左心室重构强度和增加正性肌力作用的能力的基础。
